Jenny Davies is a life sciences patent specialist in the Intellectual Property team. Her Masters in Molecular and Cellular Biochemistry from Oxford University and wealth of experience across the Life Sciences and Medical Device sectors have facilitated her roles as the Lead Associate on ground-breaking patent litigation up to the UK Court of Appeal. She has also been instrumental on a range of highly complex pharmaceutical deals worth billions of dollars.
Jenny provides strategic advice to help clients protect and exploit their R&D investment in the Life Sciences sector. Jenny builds strong working relationships with her clients to better understand their business, drivers and the commercial and technical challenges they face.
Clients praise her "endless determination", "formidable intellect" and are "deeply impressed" with her "unusual capacity to think creatively".
A highlight of Jenny's contentious portfolio is her work on biological therapies. Jenny acted for the Kennedy Trust for Rheumatology Research in the first dispute involving biological therapies in the UK, and was the Lead Associate in the billion-dollar Fujifilm Kyowa Kirin Biologics v AbbVie case securing for Fujifilm a ground-breaking form of declaratory relief in preparation for its pharmaceutical launch, in a global market worth over $16bn per year and over £400m in the UK alone.
Jenny assisted in defending H. Lundbeck in a leading case involving its top-selling anti-depressant enantiomer drug, Escitalopram. Jenny drew on her scientific background to navigate the highly complex litigation, involving extensive organic chemistry experiments.
Jenny has worked with a leading medical device company to assert its patents in a complex cross-border dispute, and represented Brightwake Limited (Advancis Medical) in successfully defending two patent infringement claims relating to its wound care products. Jenny's work has also spanned areas including gene patents, inhalable and injectable products, opiod pharmaceuticals, industrial chemical manufacture and chemical patents relating to industrial materials.
Assisting clients with global IP concerns, Jenny has coordinated cross-border litigation and an international IP enforcement program spanning 20 jurisdictions, including a global online IP enforcement program.
Jenny's transactional life sciences experience is also extensive, ranging from modest patent licenses and distribution agreements to highly-complex, high-value licensing and collaboration deals valued up to $8.5 billion. Clients commented that Jenny has a "very commercial mindset" and "her attention to detail and devotion to the task at hand is indeed impressive."
Jenny was seconded to the Gowling WLG China office as Interim Chief Representative Officer in 2014. Her work in China enabled her to develop a wealth of experience in this important jurisdiction and saw her acting for the Guangzhou office's largest client, with over 100 infringement matters to date.